



## Quest Diagnostics to Provide Lab Services to Johns Hopkins Health System

May 12, 1998

**TETERBORO, N.J., MAY 12, 1998**-Quest Diagnostics Incorporated (NYSE: DGX) today announced it has entered into an agreement with Johns Hopkins Health System of Baltimore, Maryland, to provide multiple clinical services.

Under the agreement with Johns Hopkins' Department of Pathology, Quest Diagnostics will provide clinical reference laboratory, logistics and information services to a number of Johns Hopkins Health System hospitals located in the Baltimore/Washington, D.C. area -- including Johns Hopkins Hospital and Bayview Medical Center.

David Zewe, Vice President of Sales for Quest Diagnostics, said, "We are delighted with the opportunity to work with Johns Hopkins, whose reputation for excellence is well-known."

Johns Hopkins Health System was selected by U.S. News and World Report as the top-rated health care system in the nation in each of the last seven years. The Quest Diagnostics laboratory in Baltimore will serve as the hub for providing services to the Johns Hopkins member hospitals.

Quest Diagnostics Incorporated is one of the nation's leading providers of diagnostic testing, information and services with laboratories across the United States. The wide variety of tests performed on human tissue and fluids help doctors and hospitals diagnose, treat and monitor disease. Its Nichols Institute unit conducts research, specializes in esoteric testing using genetic screening and other advanced technologies, performs clinical studies testing, and manufactures and distributes diagnostic test kits and instruments. Quest Informatics collects and analyzes laboratory, pharmaceutical and other data to help large health care customers identify and monitor patients who are at-risk for certain diseases. Visit our web site at: [www.questdiagnostics.com](http://www.questdiagnostics.com).

The statements in this press release which are not historical facts or information are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 1997 Form 10-K.